A Phase 4 interventional study of K-CAB in Helicobacter Pylori-positive With Functional Dyspepsia, sponsored by Wonkwang University Hospital. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-03-28.
Sponsored by Wonkwang University Hospital · Phase 4, Interventional, and Treatment
In patients with Helicobacter pylori-positive functional dyspepsia, long-term follow-up for 6 months after standard triple therapy first-line eradication treatment, the rate of symptom disappearance and degree of improvement of functional dyspepsia were confirmed through changes in symptom scores and changes in drug usage, and eradication treatment The purpose of this study is to confirm the rate of symptom disappearance according to the results.
363 studies on the registry are indexed under Dyspepsia; 51 are open to participants now.
This study's planned enrollment of 315 is above the median of 87 across 297 interventional studies indexed under Dyspepsia.
Browse Dyspepsia studies →Wonkwang University Hospital is the lead sponsor of 26 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
single group
Drug: K-CAB
Tegoprazan 50 mg 1 tab twice daily Amoxicillin 500mg 2 cap twice daily Clarithromycin 500mg 1tab twice daily
Rate of disappearance of dyspepsia symptoms
Rate of disappearance of dyspepsia symptoms after 6 months of eradication treatment
Time frame: Day 176
Improvement rate of dyspepsia symptoms
Change rate of dyspepsia symptoms after 3 months and 6 months of eradication treatment
Time frame: Day 92, Day 176
Number of days of dyspepsia drug administration
Number of days of dyspepsia drug administration after 3 months and 6 months of eradication treatment compared to baseline
Time frame: Day 92, Day 176
This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wonkwang University Hospital